Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study.
COMT inhibitor
Japanese
Parkinson's disease
opicapone
pharmacokinetic
phase 1
Journal
Clinical pharmacology in drug development
ISSN: 2160-7648
Titre abrégé: Clin Pharmacol Drug Dev
Pays: United States
ID NLM: 101572899
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
21
01
2020
accepted:
07
03
2020
pubmed:
28
5
2020
medline:
15
12
2021
entrez:
28
5
2020
Statut:
ppublish
Résumé
Opicapone, a peripheral, long-acting catechol-O-methyltransferase inhibitor has been shown to improve wearing-off phenomenon in randomized, double-blind studies. This study compared the pharmacokinetic characteristics of opicapone small-tablet and size 1 capsule formulations after single oral administration to healthy Japanese subjects. In this open-label, randomized, 2-way and 2-period crossover phase 1 study, 48 healthy male subjects (aged 20 to 45 years; body mass index, 18.5 to <30.0 kg/m
Identifiants
pubmed: 32459885
doi: 10.1002/cpdd.802
pmc: PMC7891373
doi:
Substances chimiques
Capsules
0
Catechol O-Methyltransferase Inhibitors
0
Oxadiazoles
0
Tablets
0
opicapone
Y5929UIJ5N
Types de publication
Clinical Trial, Phase I
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-179Informations de copyright
© 2020 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Références
Clin Pharmacol Drug Dev. 2016 May;5(3):232-40
pubmed: 27163503
Clin Pharmacokinet. 2013 Feb;52(2):139-51
pubmed: 23248072
Nat Clin Pract Neurol. 2006 Jul;2(7):382-92
pubmed: 16932589
Lancet Neurol. 2018 Nov;17(11):939-953
pubmed: 30287051
JAMA Neurol. 2017 Feb 1;74(2):197-206
pubmed: 28027332
Br J Clin Pharmacol. 2013 Nov;76(5):763-75
pubmed: 23336248
Lancet Neurol. 2016 Feb;15(2):154-165
pubmed: 26725544
Neurodegener Dis Manag. 2018 Oct;8(5):349-360
pubmed: 29975112
Br J Clin Pharmacol. 2017 Mar;83(3):540-553
pubmed: 27763682
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):353-360
pubmed: 29345156
Drug Des Devel Ther. 2017 Jan 09;11:143-151
pubmed: 28123288
Eur J Neurol. 2015 May;22(5):815-25, e56
pubmed: 25649051
Clin Pharmacol Drug Dev. 2016 Mar;5(2):150-61
pubmed: 27138028